{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:49:47Z","timestamp":1790254187869,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12672-017-0303-8","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T17:43:43Z","timestamp":1501091023000},"page":"330-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma\/Paraganglioma Patients"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-3289","authenticated-orcid":false,"given":"Julien","family":"Hadoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Terroir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Al Ghuzlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"D\u00e9andr\u00e9is","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Goere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"De Baere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"key":"303_CR1","unstructured":"DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics of tumours of endocrine organs. IARC WHO Classification of Tumours"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F et al (2014) Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171:R111\u2013R122. doi:10.1530\/EJE-14-0113","journal-title":"Eur J Endocrinol"},{"key":"303_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"C Jimenez","year":"2013","unstructured":"Jimenez C, Rohren E, Habra MA et al (2013) Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 15:356\u2013371. doi:10.1007\/s11912-013-0320-x","journal-title":"Curr Oncol Rep"},{"key":"303_CR4","doi-asserted-by":"publisher","unstructured":"Hescot S, Leboulleux S, Amar L et al (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. doi:10.1210\/jc.2013-1907","DOI":"10.1210\/jc.2013-1907"},{"key":"303_CR5","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Palmer JL, Hofmann M-C et al (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98:1492\u20131497. doi:10.1210\/jc.2012-4231","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 7","key":"303_CR6","doi-asserted-by":"publisher","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","volume":"23","author":"A Berruti","year":"2012","unstructured":"Berruti A, Baudin E, Gelderblom H et al (2012) Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii131\u2013vii138. doi:10.1093\/annonc\/mds231","journal-title":"Ann Oncol"},{"key":"303_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.bpg.2013.01.001","volume":"26","author":"K \u00d6berg","year":"2012","unstructured":"\u00d6berg K (2012) Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 26:833\u2013841. doi:10.1016\/j.bpg.2013.01.001","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"10","key":"303_CR8","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","volume":"72","author":"E Bajetta","year":"1993","unstructured":"Bajetta E, Zilembo N, Di Bartolomeo M et al (1993) Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: a study by the Italian trials in Medical Oncology Group. Cancer 72(10):3099\u20133105","journal-title":"Cancer"},{"key":"303_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1677\/ERC-09-0104","volume":"16","author":"L Dahan","year":"2009","unstructured":"Dahan L, Bonnetain F, Rougier P et al (2009) Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 16:1351\u20131361. doi:10.1677\/ERC-09-0104","journal-title":"Endocr Relat Cancer"},{"key":"303_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","volume":"26","author":"ME Caplin","year":"2015","unstructured":"Caplin ME, Baudin E, Ferolla P et al (2015) Pulmonary neuroendocrine carcinoid tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 26:1604\u20131620. doi:10.1093\/annonc\/mdv041","journal-title":"Ann Oncol"},{"key":"303_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185. doi:10.1159\/000443167","journal-title":"Neuroendocrinology"},{"key":"303_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5603\/EP.2013.0020","volume":"64","author":"E Motylewska","year":"2013","unstructured":"Motylewska E, Lawnicka H, Kowalewicz-Kulbat M et al (2013) Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro. Endokrynol Pol 64:368\u2013374. doi:10.5603\/EP.2013.0020","journal-title":"Endokrynol Pol"},{"key":"303_CR13","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/ERC-16-0431","volume":"24","author":"T Bahougne","year":"2017","unstructured":"Bahougne T, Imperiale A, Averous G et al (2017) Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma. Endocr Relat Cancer 24:L7\u2013L11. doi:10.1530\/ERC-16-0431","journal-title":"Endocr Relat Cancer"},{"key":"303_CR14","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec J-Y et al (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135:2711\u20132720. doi:10.1002\/ijc.28913","journal-title":"Int J Cancer"},{"key":"303_CR15","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Chougnet CN, Habra MA et al (2012) Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97:4040\u20134050. doi:10.1210\/jc.2012-2356","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1055\/s-0032-1304594","volume":"44","author":"A Buffet","year":"2012","unstructured":"Buffet A, Venisse A, Nau V et al (2012) A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 44:359\u2013366. doi:10.1055\/s-0032-1304594","journal-title":"Horm Metab Res"},{"issue":"Suppl 2","key":"303_CR17","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/annonc\/12.suppl_2.S79","volume":"12","author":"E Baudin","year":"2001","unstructured":"Baudin E, Bidart JM, Bachelot A et al (2001) Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12(Suppl 2):S79\u2013S82","journal-title":"Ann Oncol"},{"issue":"8","key":"303_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/bjc.1998.635","volume":"78","author":"E Baudin","year":"1998","unstructured":"Baudin E, Gigliotti A, Ducreux M et al (1998) Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78(8):1102\u20131107","journal-title":"Br J Cancer"},{"key":"303_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1196\/annals.1353.042","volume":"1073","author":"L Amar","year":"2006","unstructured":"Amar L, Peyrard S, Rossignol P et al (2006) Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas. Ann N Y Acad Sci 1073:383\u2013391. doi:10.1196\/annals.1353.042","journal-title":"Ann N Y Acad Sci"},{"key":"303_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1210\/jc.2010-2022","volume":"96","author":"R Abgral","year":"2011","unstructured":"Abgral R, Leboulleux S, D\u00e9andreis D et al (2011) Performance of (18) fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (\u226510%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 96:665\u2013671. doi:10.1210\/jc.2010-2022","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","volume":"23","author":"C Dromain","year":"2005","unstructured":"Dromain C, de Baere T, Lumbroso J et al (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23:70\u201378. doi:10.1200\/JCO.2005.01.013","journal-title":"J Clin Oncol"},{"key":"303_CR22","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1210\/jc.2008-0459","volume":"93","author":"S Leboulleux","year":"2008","unstructured":"Leboulleux S, Dromain C, Vataire AL et al (2008) Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93:3021\u20133028. doi:10.1210\/jc.2008-0459","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/jir.2006.26.8","volume":"26","author":"ME Pavel","year":"2006","unstructured":"Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFN-\u03b1 in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interf Cytokine Res 26:8\u201313. doi:10.1089\/jir.2006.26.8","journal-title":"J Interf Cytokine Res"},{"key":"303_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.diii.2014.04.004","volume":"95","author":"F Deschamps","year":"2014","unstructured":"Deschamps F, Farouil G, de Baere T (2014) Percutaneous ablation of bone tumors. Diagn Interv Imaging 95:659\u2013663. doi:10.1016\/j.diii.2014.04.004","journal-title":"Diagn Interv Imaging"},{"key":"303_CR25","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00330-014-3202-1","volume":"24","author":"F Deschamps","year":"2014","unstructured":"Deschamps F, Farouil G, Ternes N et al (2014) Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol 24:1971\u20131980. doi:10.1007\/s00330-014-3202-1","journal-title":"Eur Radiol"},{"key":"303_CR26","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1210\/jc.2012-2975","volume":"98","author":"A-P Gimenez-Roqueplo","year":"2013","unstructured":"Gimenez-Roqueplo A-P, Caumont-Prim A, Houzard C et al (2013) Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 98:E162\u2013E173. doi:10.1210\/jc.2012-2975","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR27","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"S Faiss","year":"2003","unstructured":"Faiss S, Pape U-F, B\u00f6hmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors\u2014the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689\u20132696. doi:10.1200\/JCO.2003.12.142","journal-title":"J Clin Oncol"},{"key":"303_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/bjs.4149","volume":"90","author":"L K\u00f6lby","year":"2003","unstructured":"K\u00f6lby L, Persson G, Franz\u00e9n S, Ahr\u00e9n B (2003) Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687\u2013693. doi:10.1002\/bjs.4149","journal-title":"Br J Surg"},{"key":"303_CR29","first-page":"6601","volume":"34","author":"E Mirvis","year":"2014","unstructured":"Mirvis E, Mandair D, Garcia-Hernandez J et al (2014) Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study. Anticancer Res 34:6601\u20136607","journal-title":"Anticancer Res"},{"key":"303_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E et al (2008) Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020\u20132028. doi:10.1002\/cncr.23812","journal-title":"Cancer"},{"key":"303_CR31","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA et al (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118:2804\u20132812. doi:10.1002\/cncr.26577","journal-title":"Cancer"},{"key":"303_CR32","doi-asserted-by":"publisher","unstructured":"Fishbein L, Ben-Maimon S, Keefe S et al (2017) SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer. doi:10.1530\/ERC-17-0086","DOI":"10.1530\/ERC-17-0086"},{"key":"303_CR33","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, Goldsby R, Matthay KK et al (2009) Phase II study of high-dose 131Imetaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27:4162\u20134168. doi:10.1200\/JCO.2008.21.3496","journal-title":"J Clin Oncol"},{"key":"303_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","volume":"46","author":"JA Carrasquillo","year":"2016","unstructured":"Carrasquillo JA, Pandit-Taskar N, Chen CC (2016) I-131 Metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma. Semin Nucl Med 46:203\u2013214. doi:10.1053\/j.semnuclmed.2016.01.011","journal-title":"Semin Nucl Med"},{"issue":"4","key":"303_CR35","first-page":"284","volume":"35","author":"M Krempf","year":"1991","unstructured":"Krempf M, Lumbroso J, Mornex R et al (1991) Treatment of malignant pheochromocytoma with 131metaiodobenzylguanidine: a French multicenter study. J Nucl Biol Med 35(4):284\u2013287","journal-title":"J Nucl Biol Med"},{"key":"303_CR36","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","volume":"134","author":"SD Safford","year":"2003","unstructured":"Safford SD, Coleman RE, Gockerman JP et al (2003) Iodine \u2212131 Imetaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956\u2013962; discussion 962-963. doi:10.1016\/S0039","journal-title":"Surgery"},{"key":"303_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","volume":"27","author":"H Wakabayashi","year":"2013","unstructured":"Wakabayashi H, Taki J, Inaki A et al (2013) Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med 27:839\u2013846. doi:10.1007\/s12149-013-0755-z","journal-title":"Ann Nucl Med"},{"issue":"3","key":"303_CR38","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1128\/MCB.15.3.1613","volume":"15","author":"N Asai","year":"1995","unstructured":"Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15(3):1613\u20131619","journal-title":"Mol Cell Biol"},{"key":"303_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K et al (2013) Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 4:103\u2013110. doi:10.1007\/s12672-013-0133-2","journal-title":"Horm Cancer"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-017-0303-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-017-0303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-017-0303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T17:12:39Z","timestamp":1609261959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-017-0303-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":39,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s12672-017-0303-8","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}